Spitfire List Web site and blog of anti-fascist researcher and radio personality Dave Emory.

Search Results

Your search for 'Ebola' returned 47 results.

Ebola: The German/American/Biological Warfare Connection

Although we have no hard infor­ma­tion of a pos­si­ble bio­log­i­cal war­fare link to the out­break, an arti­cle from for­mer Naval Intel­li­gence offi­cer Wayne Mad­sen is worth con­sid­er­ing in that regard. In 2009, Ger­many was pon­der­ing the ship­ment of dead­ly pathogens, includ­ing Ebo­la virus to Ft. Det­rick in Mary­land. They voiced con­cern about the pos­si­bil­i­ty that the sam­ples might be weaponized, pos­si­bly giv­ing them­selves plau­si­ble deni­a­bil­i­ty in the event that they were used for bio­log­i­cal war pur­pos­es. All of the con­tents of this web­site as of 10/2/2014–Dave Emory’s 35+ years of research and broadcasting–as well as hours of video­taped lec­tures are avail­able on a 32GB flash dri­ve.

FTR #820 Interview with Ed Haslam about Ebola and the New Edition of “Dr. Mary’s Monkey”

Revis­it­ing the hero­ic Ed Haslam, we high­light new points of infor­ma­tion from his book “Dr. Mary’s Mon­key,” as well as set­ting forth infor­ma­tion about Ebo­la, indi­cat­ing that the offi­cial ver­sion of the evo­lu­tion of that dead­ly dis­ease is bad­ly skewed. Key points of infor­ma­tion in Ed’s new edi­tion include the J. Edgar Hoover’s order to pre­clude FBI involve­ment in the inves­ti­ga­tion of Dr. Mary Sher­man’s mur­der; Mey­er Lan­sky aide Chauncey Holt’s links to Lee Har­vey Oswald, the CIA and Oper­a­tion Mon­goose (the Agen­cy’s anti-Cas­tro effort); Stan­ley Stumpf’s pos­si­ble role in mov­ing Dr. Mary Sher­man’s body; the War­ren Com­mis­sion’s omis­sion of Oswald’s signed time cards from the Reil­ly Cof­fee Com­pa­ny; Vic­to­ria and Owen Hawes’ account of Oswald’s vis­its to a neigh­bor of Dr. Mary Sher­man and the pos­si­ble dis­pos­al of bio-waste in the neigh­bor’s toi­let; crime scene pho­tos of Dr. Mary Sher­man’d corpse that dis­prove the offi­cial ver­sion of her killing; the CIA’s com­plete redac­tion of “Crown Jew­el #1”–the Agen­cy’s activ­i­ties between the late 1950’s and 1964.

FTR #324 Biological Warfare, AIDS, Ebola & Apartheid

Record­ed less than 48 hours before the 9/11 attacks, fore­shad­ow­ing the anthrax attacks that fol­lowed, and offer­ing pos­si­ble clues as to why, view­ing worlds of clan­des­tine fas­cist pol­i­tics, the intel­li­gence com­mu­ni­ty and bio­log­i­cal war­fare research.

FTR #17 The Ebola Virus

Lis­ten now: One Seg­ment This seg­ment sets forth infor­ma­tion indi­cat­ing that the dead­ly Ebo­la virus that has emerged in Africa may be a man-made virus that was devel­oped in West­ern bio­log­i­cal war­fare pro­grams. Rely­ing on infor­ma­tion pre­sent­ed in a Ger­man tele­vi­sion doc­u­men­tary and accessed in a mag­a­zine called The New African, the broad­cast notes that […]

FTR #1139 The Anthrax Attacks, the Invasion of Iraq and Expansion of Biological Warfare Capabilities

As the title indi­cates, this pro­gram presents polit­i­cal and his­tor­i­cal foun­da­tion for the expo­nen­tial expan­sion of Amer­i­can bio­log­i­cal war­fare infra­struc­ture fol­low­ing the 2001 anthrax attacks.

Impor­tant back­ground infor­ma­tion comes from the Whit­ney Webb arti­cle about DARPA spend­ing on bat-borne coro­n­avirus­es.

The Broad­cast­ing Board of Governors–a CIA “derivative”–and The Wash­ing­ton Times (owned by the Uni­fi­ca­tion Church) helped devel­op dis­in­for­ma­tion about SARS CoV‑2 com­ing from a Chi­nese Bio­log­i­cal War­fare lab. Both were instru­men­tal in hyp­ing the anthrax attacks as authored by Sad­dam Hus­sein, as well. The Wash­ing­ton Times also pre­sent­ed infor­ma­tion float­ed by Steven Hat­fill that fore­shad­owed sub­se­quent charges that Sad­dam Hus­sein was devel­op­ing bioweapons and was behind the 2001 anthrax attacks.

In addi­tion, the Project For a New Amer­i­can Cen­tu­ry was advanc­ing an agen­da in which genet­i­cal­ly-engi­neered bio­log­i­cal war­fare tech­nol­o­gy as essen­tial to con­tin­ued Amer­i­can glob­al dom­i­nance.

As will be seen below, a key func­tionary in the PNAC milieu was for­mer Sec­re­tary of Defense Don­ald Rums­feld, for­mer chair­man of the board of Gilead Sci­ences.

In FTR #‘s 1135, 1136 and 1137, we relied heav­i­ly on the Kris New­by’s Bit­ten: The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons. In that book, Ms. New­by net­worked with a group of expe­ri­enced, Cold War bio­log­i­cal war­fare pro­fes­sion­als whom she termed “the Brain Trust.” They were con­vinced that Fort Det­rick sci­en­tist Bruce Ivins–the “lone nut” who con­ve­nient­ly com­mit­ted sui­cide and was fin­gered as the sole per­pe­tra­tor of the 2001 anthrax attacks–was framed. ” . . . . Among oth­er sub­jects, they dis­cussed  . . . tech­ni­cal details on why they believed that their col­league Bruce Ivins had been framed as the anthrax mail­er . . . .”

Much of the pro­gram cen­ters on the 2001 attacks and the sus­pi­cion that focused on Steven Hat­fill as a pos­si­ble per­pe­tra­tor of them. Although exon­er­at­ed in the attacks, Hat­fill was the focal point of con­sid­er­able sus­pi­cion in con­nec­tion with the event. Our sus­pi­cion is that he is an oper­a­tive of one or anoth­er intel­li­gence agency, CIA being the most prob­a­ble.

We sus­pect that the anthrax attacks were a provo­ca­tion aimed at jus­ti­fy­ing the inva­sion of Iraq and spurring devel­op­ment of the U.S. bio­log­i­cal war­fare capa­bil­i­ty.

Of par­tic­u­lar note is the appar­ent “oper­a­tional Teflon” worn by Hat­fill. Although cir­cum­stan­tial evi­dence point­ed in his direc­tion, he appeared to be alto­geth­er “off lim­its” to inves­tiga­tive ele­ments of Alpha­bet Soup. Don Fos­ter not­ed the unusu­al treat­ment accord­ed to Hat­fill by the pow­ers that be.

Of sig­nif­i­cance, as well, are the numer­ous exam­ples of fore­shad­ow­ing of the foren­sic cir­cum­stances of the anthrax attacks, as well as oth­er “false alarm” inci­dents that occurred before and after the fatal attacks. It requires lit­tle to see state­ments and arti­cles by nota­bles such as Bill Patrick and the seem­ing­ly ubiq­ui­tous Steven Hat­fill as lay­ing a foun­da­tion of cred­i­bil­i­ty for sub­se­quent events.

Note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty.

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Steven Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”
2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

As not­ed in past pro­grams, Gilead Sci­ences is very well-con­nect­ed pro­fes­sion­al­ly, with for­mer Sec­re­tary of Defense Don­ald Rums­feld (among oth­er polit­i­cal lumi­nar­ies) serv­ing on its board of direc­tors. Rums­feld was chair­man of the board from 1997 until he left in 2001 to become George W. Bush’s Sec­re­tary of Defense.

Rums­feld was Sec­re­tary of Defense dur­ing the peri­od in which the 2001 anthrax attacks occurred.

Dur­ing the post‑9/11 peri­od of explod­ing gov­ern­ment invest­ments in biode­fense pro­grams, Sec­re­tary of Defense Don­ald Rums­feld was still hold­ing onto mas­sive amounts of Gilead stock, which was increas­ing in val­ue dra­mat­i­cal­ly. What kind of rela­tion­ship did Gilead devel­op with the US biode­fense nation­al secu­ri­ty state dur­ing this peri­od? That seems like a pret­ty impor­tant ques­tion at this point in time.

The U.S. gov­ern­ment was among the cus­tomers whose pur­chas­es drove up the Gilead earn­ings and stock price: ” . . . . What’s more, the fed­er­al gov­ern­ment is emerg­ing as one of the world’s biggest cus­tomers for Tam­i­flu. In July, the Pen­ta­gon ordered $58 mil­lion worth of the treat­ment for U.S. troops around the world, and Con­gress is con­sid­er­ing a mul­ti-bil­lion dol­lar pur­chase. . . .”

Sev­er­al years into his tenure at the Pen­ta­gon, Rums­feld made a killing on the sale of Gilead Sci­ences’ stock, which rose expo­nen­tial­ly in val­ue fol­low­ing its devel­op­ment of Tam­i­flu as a treat­ment for H5N1 avian flu.” . . . . The firm made a loss in 2003, the year before con­cern about bird flu start­ed. Then rev­enues from Tam­i­flu almost quadru­pled, to $44.6m, help­ing put the com­pa­ny well into the black. Sales almost quadru­pled again, to $161.6m last year. Dur­ing this time the share price tre­bled. Mr Rums­feld sold some of his Gilead shares in 2004 reap­ing – accord­ing to the finan­cial dis­clo­sure report he is required to make each year – cap­i­tal gains of more than $5m. The report showed that he still had up to $25m-worth of shares at the end of 2004, and at least one ana­lyst believes his stake has grown well beyond that fig­ure, as the share price has soared. . . .”

Don­ald Rums­feld was a sig­na­to­ry to the 1998 let­ter to Pres­i­dent Clin­ton by the Project for a New Amer­i­can Cen­tu­ry. That let­ter advo­cat­ed a hard­er line against Iraq. ” . . . . Rums­feld has strong ties to the Intel­li­gence Com­mu­ni­ty, as well as to the Atlantic Insti­tute, and is a mem­ber of the Bilder­berg group. He is a finan­cial sup­port­er for the Cen­ter for Secu­ri­ty Pol­i­cy. Rums­feld was one of the sign­ers of the Jan­u­ary 26, 1998, Project for the New Amer­i­can Cen­tu­ry (PNAC) let­ter sent to Pres­i­dent William Jef­fer­son Clin­ton. . . .”

DARPA and the Pen­ta­gon have into the appli­ca­tion of genet­ic engi­neer­ing in order to cre­ate eth­no-spe­cif­ic bio­log­i­cal war­fare weapons, as dis­cussed by the Project for a New Amer­i­can Cen­tu­ry.

In past pro­grams and posts, we have not­ed that DARPA was research­ing  bat-borne coro­n­avirus­es.  One can but won­der to what extent the PNAC doc­trine helped spawn the DARPA research into coro­n­avirus­es and, pos­si­bly, the Covid-19 pan­dem­ic.

FTR #1138 Bio-Psy-Op Apocalypse Now, Part 10: Bad Medicine

Con­tin­u­ing dis­cus­sion about drug treat­ments for, and vac­cines to pre­vent, Covid-19, this pro­gram sets forth infor­ma­tion about the ongo­ing pro­fes­sion­al mas­sag­ing of Gilead Sci­ences’ anti-viral remde­sivir. Only mod­est­ly suc­cess­ful against SARS Cov‑2 (the virus that caus­es Covid-19), remde­sivir has been pro­pelled to the fore­front of treat­ment reg­i­mens for the pan­dem­ic.

Of par­tic­u­lar inter­est are the cir­cum­stances sur­round­ing the CDC’s clo­sure of the U.S. Army Med­ical Research Insti­tute of Infec­tious Dis­eases. The USAMRIID–located at Ft. Detrick–had host­ed Gilead Sci­ences’ ani­mal tri­als of remde­sivir. Remde­sivir was devel­oped to com­bat Ebo­la, and was a fail­ure in its ini­tial pro­fes­sion­al iter­a­tion.

In March of 2019, rhe­sus macaques were infect­ed with Ebo­la at the USAMRIID as part of a project to allow remde­sivir to be mar­ket­ed as an Ebo­la treat­ment with­out meet­ing the pro­fes­sion­al stan­dards of human test­ing. ” . . . This agree­ment was made pos­si­ble through a 2018 Nat­ur­al His­to­ry Study (NHS) of Ebo­la virus con­duct­ed by USAMRIID in close col­lab­o­ra­tion with Gilead Sci­ences, Inc., the spon­sor of remde­sivir devel­op­ment . . .”

Many of the safe­ty vio­la­tions cit­ed by the CDC in its cri­tique of USAMRIID safe­ty and secu­ri­ty pro­ce­dures con­cerned “non-human pri­mates” infect­ed with one or more “select agents” that were not named. The term “select agent” refers to a pathogen being used in lab­o­ra­to­ry pro­ce­dures. Whether the “select agent” was Ebo­la, and whether the safe­ty laps­es were in con­nec­tion with the remdesivir/rhesus mon­key tri­als was not dis­closed.

” . . . . Sev­er­al of the lab­o­ra­to­ry vio­la­tions the CDC not­ed in 2019 con­cerned ‘non-human pri­mates’ infect­ed with a ‘select agent’, the iden­ti­ty of which is unknown — it was redact­ed in all received doc­u­ments, because dis­clos­ing the iden­ti­ty and loca­tion of the agent would endan­ger pub­lic health or safe­ty, the agency says. In addi­tion to Ebo­la, the lab works with oth­er dead­ly agents like anthrax and small­pox. . . ..”

If, for the sake of argu­ment, SARS-CoV­‑2 research was indeed tak­ing plac­ing there was a very real risk of it escap­ing.

Remde­sivir failed in its human tri­als as a treat­ment for Ebo­la: ” . . . . The antivi­ral drug remde­sivir, made by Gilead, under­per­formed ZMapp. . . .  Remde­sivir and ZMapp have been dropped from the tri­al. . . .”

Fol­low­ing that dis­mal per­for­mance against Ebo­la, Gilead Sci­ences recast remde­sivir as a broad spec­trum antivi­ral, a mar­ket­ing approach that has led to the drug being autho­rized to treat Covid-19.

In that pro­fes­sion­al rein­car­na­tion, it demon­strat­ed alto­geth­er mod­est suc­cess in Covid-19 tri­als that were pro­fes­sion­al­ly crit­i­cized and which were bad­ly skewed from a method­olog­i­cal stand­point. 

After a tight­en­ing of pro­fes­sion­al method­olog­i­cal stan­dards at the USAMRIID, it was dis­closed that most of the insti­tu­tion’s oper­a­tives are pri­vate con­trac­tors! From the stand­point of insti­tu­tion­al secu­ri­ty, the broad use of pri­vate con­trac­tors ren­ders USAMRIID sub­ject to pen­e­tra­tion by any num­ber of poten­tial mis­cre­ants. ” . . . . ‘A major­i­ty of our lab­o­ra­to­ry work­ers are contractors–putting teeth in the con­tracts to ensure they’re fol­low­ing the shalls, wills and musts are things we’ve done in the inter­im,’ said [Brigadier Gen­er­al Mike] Tal­ley. . . .”

As not­ed in past pro­grams, Gilead Sci­ences is very well-con­nect­ed pro­fes­sion­al­ly, with for­mer Sec­re­tary of Defense Don­ald Rums­feld (among oth­er polit­i­cal lumi­nar­ies) serv­ing on its board of direc­tors. Rums­feld was chair­man of the board from 1997 until he left in 2001 to become George W. Bush’s Sec­re­tary of Defense. The fir­m’s stock has been heav­i­ly invest­ed in by hedge funds, includ­ing Robert Mer­cer’s Renais­sance Tech­nolo­gies. Gilead Sci­ences’ stock has been a major dri­ver of the stock mar­ket’s per­for­mance.

Sev­er­al years into his tenure at the Pen­ta­gon, Rums­feld made a killing on the sale of Gilead Sci­ences’ stock, which rose expo­nen­tial­ly in val­ue fol­low­ing its devel­op­ment of Tam­i­flu as a treat­ment for H5N1 avian flu. ” . . . . The firm made a loss in 2003, the year before con­cern about bird flu start­ed. Then rev­enues from Tam­i­flu almost quadru­pled, to $44.6m, help­ing put the com­pa­ny well into the black. Sales almost quadru­pled again, to $161.6m last year. Dur­ing this time the share price tre­bled. Mr Rums­feld sold some of his Gilead shares in 2004 reap­ing – accord­ing to the finan­cial dis­clo­sure report he is required to make each year – cap­i­tal gains of more than $5m. The report showed that he still had up to $25m-worth of shares at the end of 2004, and at least one ana­lyst believes his stake has grown well beyond that fig­ure, as the share price has soared. . . .”

The U.S. gov­ern­ment was among the cus­tomers whose pur­chas­es drove up the Gilead earn­ings and stock price: ” . . . . What’s more, the fed­er­al gov­ern­ment is emerg­ing as one of the world’s biggest cus­tomers for Tam­i­flu. In July, the Pen­ta­gon ordered $58 mil­lion worth of the treat­ment for U.S. troops around the world, and Con­gress is con­sid­er­ing a mul­ti-bil­lion dol­lar pur­chase. . . .”

(Recall that the H5N1 virus is one of the gain-of-func­tion exper­i­ments that was sus­pend­ed in 2014 and then green­light­ed by the Trump admin­is­tra­tion in 2017. Those exper­i­ments engi­neered the virus to infect fer­rets, a maneu­ver that made the virus com­mu­ni­ca­ble by upper res­pi­ra­to­ry activ­i­ty. One can but won­der if those G‑O-F exper­i­ments were con­nect­ed to the recast­ing of remde­sivir as a broad spec­trum antivi­ral.)

Dur­ing the post‑9/11 peri­od of explod­ing gov­ern­ment invest­ments in biode­fense pro­grams, Rums­feld was still hold­ing onto mas­sive amounts of Gilead­’s stock, which was rapid­ly increas­ing in val­ue. What kind of rela­tion­ship did Gilead devel­op with the US biode­fense nation­al secu­ri­ty state dur­ing this peri­od? That seems like an  impor­tant ques­tion at this point in time. 

In FTR #1136, we not­ed that the med­ical and sci­en­tif­ic inter­ests in charge of Lyme Dis­ease treat­ment and diag­no­sis were not only finan­cial ben­e­fi­cia­ries of the ther­a­peu­tic sta­tus quo, but were also tasked with dis­cred­it­ing Lyme patients and physi­cians who chal­lenged that sta­tus quo. In light of the evi­dence that Lyme Dis­ease was the out­growth of bio­log­i­cal war­fare research, the pro­fes­sion­al rela­tion­ship between gov­ern­men­tal insti­tu­tions involved with BW research and biotech­nol­o­gy and phar­ma­ceu­ti­cal firms prof­it­ing from the treat­ment of dis­eases those insti­tu­tions devel­op and deploy is worth con­tem­plat­ing! 

Pre­vi­ous broad­casts have doc­u­ment­ed the skewed, pref­er­en­tial treat­ment of remde­sivir by pow­er­ful polit­i­cal and finan­cial play­ers with sig­nif­i­cant invest­ment in the suc­cess of remde­sivir.

The pro­gram con­cludes with three updates of pre­vi­ous lines of inquiry”

1.–Past pro­grams have high­light­ed pos­si­ble vec­tors into Wuhan for the SARS CoV‑2. We note that there was a work­shop held at the Wuhan lab in ear­ly Novem­ber of 2019, fea­tur­ing sci­en­tists and bio-lab pro­fes­sion­als from around the world. This con­fer­ence may have been among the oppor­tu­ni­ties to spread the virus, and/or a co-vec­tor and/or cross-vec­tor. ” . . . . The work­shop is designed for lab­o­ra­to­ry man­agers and direc­tors, research and lab­o­ra­to­ry staffs main­ly from devel­op­ing coun­tries who plan to car­ry out infec­tious dis­ease research in biosafe­ty facil­i­ties. The work­shop will address key aspects of biosafe­ty and pro­vide prac­ti­cal train­ing in high lev­el biosafe­ty lab­o­ra­to­ries (BSL). This work­shop will invite a group of well-known schol­ars and experts from relat­ed fields at home and abroad to pro­vide the the­o­ret­i­cal and prac­ti­cal cours­es. . . .”
2.–As not­ed in past pro­grams the Wuhan Insti­tute of Virol­o­gy was engaged in bat-borne coro­n­avirus research, which includ­ed the genet­ic mod­i­fi­ca­tion of such organ­isms. That research was a joint U.S./Chinese under­tak­ing, with the U.S. fund­ing com­ing from insti­tu­tions which have front­ed for Amer­i­can intel­li­gence and the Pen­ta­gon. That joint U.S./Chinese under­tak­ing was ter­mi­nat­ed by the Trump admin­is­tra­tion in May! In addi­tion: ” . . . . Many of the sci­en­tists at the Wuhan Insti­tute of Virol­o­gy have been trained by the U.S. government’s PREDICT project. . . . USAID’s PREDICT project . . . will end this Sep­tem­ber after 10 years and two six-month exten­sions as USAID launch­es a new project that applies the data PREDICT col­lect­ed. . . .”
3.–Other broad­casts have explored the Wuhan World Mil­i­tary Games–a mil­i­tary sports competition–as a pos­si­ble vec­tor­ing vehi­cle. We update that path of inquiry with dis­cus­sion of the U.S. del­e­ga­tion as a pos­si­ble vec­tor­ing agent for the spread of the dis­ease in the U.S. ” . . . . Con­trary to the Pentagon’s insis­tence, how­ev­er, an inves­ti­ga­tion of COVID-19 cas­es in the mil­i­tary from offi­cial and pub­lic source mate­ri­als shows that a strong cor­re­la­tion exists in COVID-19 cas­es report­ed at U.S. mil­i­tary facil­i­ties that are home bases of mem­bers of the U.S. team that went to Wuhan. Before March 31, when the Pen­ta­gon restrict­ed the release of infor­ma­tion about COVID-19 cas­es at instal­la­tions for secu­ri­ty rea­sons, infec­tions occurred at a min­i­mum of 63 mil­i­tary facil­i­ties where team mem­bers returned after the Wuhan games. Addi­tion­al­ly, the U.S. team used char­tered flights to and from the games via Seat­tle-Taco­ma Inter­na­tion­al Air­port. Wash­ing­ton was one of the ear­li­est states to show a spike in COVID-19. . . .” We also note that the U.S. del­e­ga­tion con­tained: ” . . . . nine pub­lic-affairs offi­cers . . . and two State Depart­ment per­son­nel, accord­ing to DOD doc­u­ments. . . .” “Pub­lic affairs offi­cer” is a com­mon cov­er for CIA per­son­nel.

FTR #1132 Bio-Psy-Op Apocalypse Now, Part 8: Remdesivir Uber Alles

This broad­cast details the process of vet­ting the anti-Covid-19 drug remde­sivir, high­light­ing the insti­tu­tion­al short­cuts tak­en in test­ing the prod­uct, as well as the dubi­ous nature of the bil­lion­aires net­work­ing with offi­cials involved in the approval process.

Before ana­lyz­ing remde­sivir, how­ev­er, we update dis­cus­sion about the SARS CoV‑2 virus hav­ing been engi­neered, not­ing joint U.S.-Chinese projects in which bat-borne coro­n­avirus­es were genet­i­cal­ly engi­neered. The process­es used to mod­i­fy the virus­es would not show any overt evi­dence of human manip­u­la­tion.

Most impor­tant­ly, these projects received financ­ing from insti­tu­tions with doc­u­ment­ed links to U.S. intel­li­gence and mil­i­tary inter­ests.

Research into the his­to­ry of GOF (gain-of-func­tion) work on bat coro­n­avirus­es at the Wuhan Insti­tute of Virol­o­gy indi­cates mul­ti­ple areas of U.S. intel­li­gence pres­ence in that work. 

It was pub­licly dis­closed in a 2017 paper that the US and Chi­na col­lab­o­rat­ed on “gain-of-func­tion” research on bat coro­n­avirus­es to infect humans and that the work received fund­ing from the Unit­ed States Agency for Inter­na­tion­al Development–a fre­quent cut-out for the CIA.

In addi­tion, the work was also fund­ed in part by the Nation­al Insti­tutes of Health, which have col­lab­o­rat­ed with both CIA and the Pen­ta­gon in BSL‑4 (Bio-Safe­ty-Lev­el 4) projects. 

The Wuhan Insti­tute of Virol­o­gy has also part­nered with the USAMRIID since the mid-1980’s.

Impor­tant to note is the fact that it was pub­lic infor­ma­tion that some of this work was done in a biosafe­ty-lev­el 2 lab­o­ra­to­ry, giv­ing an observ­er intent on under­tak­ing a bio­log­i­cal war­fare covert oper­a­tion against Chi­na use­ful field intel­li­gence about the vul­ner­a­bil­i­ty of WIV for such an “op.”

1.–The inves­ti­ga­tion of infec­tiv­i­ty used unde­tectable meth­ods, negat­ing arti­cles claim­ing the virus could not have been genet­i­cal­ly engi­neered: ” Evi­dence has emerged that researchers at the Wuhan Insti­tute of Virol­o­gy (WIV) in Chi­na, work­ing in col­lab­o­ra­tion with sci­en­tists in the USA, have been genet­i­cal­ly engi­neer­ing bat virus­es for the past sev­er­al years to inves­ti­gate infec­tiv­i­ty – using unde­tectable meth­ods. . . . The evi­dence rebuts claims by jour­nal­ists and some sci­en­tists that the SARS-CoV­‑2 virus respon­si­ble for the cur­rent COVID-19 pan­dem­ic could not have been genet­i­cal­ly engi­neered because it lacks the ‘signs’ or ‘sig­na­tures’ that sup­pos­ed­ly would be left behind by genet­ic engi­neer­ing tech­niques. . . .”

2.–Dr. Richard Ebright not­ed that the research was joint­ly fund­ed by the U.S. and Chi­na, that Peter Daszak (about whom we have voiced reser­va­tions in the past) was one of the Amer­i­can col­lab­o­ra­tors. Fur­ther­more, the research was fund­ed in part by USAID, a com­mon U.S. intel­li­gence cut-out. ” . . . . Dr Richard Ebright, an infec­tious dis­ease expert at Rut­gers Uni­ver­si­ty (USA), has alert­ed the pub­lic to evi­dence that WIV and US-based researchers were genet­i­cal­ly engi­neer­ing bat virus­es to inves­ti­gate their abil­i­ty to infect humans, using com­mon­ly used meth­ods that leave no sign or sig­na­ture of human manip­u­la­tion. Ebright flagged up a sci­en­tif­ic paper pub­lished in 2017 by WIV sci­en­tists, includ­ing Shi Zhengli, the virol­o­gist lead­ing the research into bat coro­n­avirus­es, work­ing in col­lab­o­ra­tion with Peter Daszak of the US-based Eco­Health Alliance. Fund­ing was shared between Chi­nese and US insti­tu­tions, the lat­ter includ­ing the US Nation­al Insti­tutes of Health and USAID. The researchers report hav­ing con­duct­ed virus infec­tiv­i­ty exper­i­ments where genet­ic mate­r­i­al is com­bined from dif­fer­ent vari­eties of SARS-relat­ed coro­n­avirus­es to form nov­el ‘chimeric’ ver­sions. This formed part of their research into what muta­tions were need­ed to allow cer­tain bat coro­n­avirus­es to bind to the human ACE2 recep­tor – a key step in the human infec­tiv­i­ty of SARS-CoV­‑2. . . .”

3.–Furthermore, the researchers used a type of genet­ic engi­neer­ing that leaves no sig­na­ture of human manip­u­la­tion: ” . . . . The WIV sci­en­tists did this, Ebright points out, ‘using ‘seam­less lig­a­tion’ pro­ce­dures that leave no sig­na­tures of human manip­u­la­tion’. This is note­wor­thy because it is a type of genet­ic engi­neer­ing that Ander­sen and his team exclud­ed from their inves­ti­ga­tion into whether SARS-CoV­‑2 could have been engi­neered – and it was in use at the very lab that is the prime sus­pect for a lab escape. . . .”

4.–In addi­tion, Ebright high­lights the 2015 work done by Ralph Bar­ic in col­lab­o­ra­tion with WIV’s Shi Zhengli–a project we have dis­cussed at length in the past: ” . . . . A group of sci­en­tists from the Uni­ver­si­ty of North Car­oli­na in the USA, with the WIV’s Shi Zhengli as a col­lab­o­ra­tor, pub­lished a study in 2015 describ­ing sim­i­lar exper­i­ments involv­ing chimeric coro­n­avirus­es, which were also cre­at­ed using stan­dard unde­tectable genet­ic engi­neer­ing tech­niques. . . .”

5.–Ebright also cites work done in a bio-safe­ty lev­el 2 lab­o­ra­to­ry. : ” . . . . Ebright points out that the paper states, ‘All work with the infec­tious virus was per­formed under biosafe­ty lev­el 2 con­di­tions’. This lev­el is suit­able for work involv­ing agents of only ‘mod­er­ate poten­tial haz­ard to per­son­nel and the envi­ron­ment’. . . .But they are not at fault in fail­ing to use BSL‑4 for this work, as SARS coro­n­avirus­es are not aerosol-trans­mit­ted. The work does, how­ev­er, fall under biosafe­ty lev­el 3, which is for work involv­ing microbes that can cause seri­ous and poten­tial­ly lethal dis­ease via inhala­tion. . . .”

6.–Dr. Jonathan Lath­am under­scored the reser­va­tions expressed by many con­cern­ing “gain-of-func­tion” exper­i­ments on these kinds of coro­n­avirus­es: ” . . . . The bio­sci­en­tist Dr Jonathan Lath­am crit­i­cised the kind of research on bat coro­n­avirus­es that has been tak­ing place in Wuhan and the USA as ‘pro­vid­ing an evo­lu­tion­ary oppor­tu­ni­ty’ for such virus­es ‘to jump into humans’. Lath­am, who has a doc­tor­ate in virol­o­gy, argues that this kind of work is sim­ply ‘pro­vid­ing oppor­tu­ni­ties for con­t­a­m­i­na­tion events and leak­ages from labs, which hap­pen on a rou­tine basis’. . . .”

U.S. Army Med­ical Research Insti­tute of Infec­tious Disease–located at Ft. Det­rick and closed by the CDC for safe­ty vio­la­tions in August, 2019.

Note, again, that the whole world was informed back in 2017 that  dan­ger­ous research involv­ing the cre­ation of bat coro­n­avirus­es to infect humans was being car­ried out in Chi­na.  Note again, that the research was fund­ed in part by the US, includ­ing USAID–a fre­quent U.S. intel­li­gence cut-out; the NIH–which has active­ly col­lab­o­rat­ed with both CIA and Pen­ta­gon. The WIV has also part­nered with the USAMRIID.

Flash for­ward a cou­ple of years and we have a night­mare virus that ini­tial­ly appeared to pop up near­by the WIV, with the Trump admin­is­tra­tion aggres­sive­ly push­ing the idea that it escaped from that lab.

In that con­text, we note the fol­low­ing:

1.–In 2017, Chi­na got approval for its first BSL‑4 lab in Wuhan, the first of sev­er­al planned BSL‑4 labs. “A lab­o­ra­to­ry in Wuhan is on the cusp of being cleared to work with the world’s most dan­ger­ous pathogens. The move is part of a plan to build between five and sev­en biosafe­ty level‑4 (BSL‑4) labs across the Chi­nese main­land by 2025, and has gen­er­at­ed much excite­ment, as well as some con­cerns. . . . Some sci­en­tists out­side Chi­na wor­ry about pathogens escap­ing, and the addi­tion of a bio­log­i­cal dimen­sion to geopo­lit­i­cal ten­sions between Chi­na and oth­er nations. . . .”

2.–As will be seen below, the pro­lif­er­a­tion of BSL‑4 labs has sparked wor­ries about “dual use” tech­nol­o­gy: ” . . . . The expan­sion of BSL-4-lab net­works in the Unit­ed States and Europe over the past 15 years — with more than a dozen now in oper­a­tion or under con­struc­tion in each region — also met with resis­tance, includ­ing ques­tions about the need for so many facil­i­ties. . . .”

3.–The above-men­tioned Richard Ebright notes that the pro­lif­er­a­tion of BSL‑4 labs will spur sus­pi­cion of “dual use” tech­nol­o­gy, in which osten­si­ble med­ical research masks bio­log­i­cal war­fare research: ” . . . . But Ebright is not con­vinced of the need for more than one BSL‑4 lab in main­land Chi­na. He sus­pects that the expan­sion there is a reac­tion to the net­works in the Unit­ed States and Europe, which he says are also unwar­rant­ed. He adds that gov­ern­ments will assume that such excess capac­i­ty is for the poten­tial devel­op­ment of bioweapons. ‘These facil­i­ties are inher­ent­ly dual use,’ he says. . . .”

In the con­text of the above arti­cles, note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty. Note that the U.S. and Europe have twelve BSL4 labs apiece, Tai­wan has two, while Chi­na has one:

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Stephen Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”

2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

Note, also that:

1.–The WIV has part­nered with the U.S. Army’s Med­ical Research Insti­tute of Infec­tious Dis­eases, locat­ed at Ft. Det­rick.

2.–In ear­ly August of 2019, short­ly before the record­ed start of the out­break in Wuhan, Chi­na, the U.S. Army Med­ical Research Insti­tute of Infec­tious Dis­eases at that facil­i­ty was closed down by the CDC due to mul­ti­ple safe­ty violations.“All research at a Fort Det­rick lab­o­ra­to­ry that han­dles high-lev­el dis­ease-caus­ing mate­r­i­al, such as Ebo­la, is on hold indef­i­nite­ly after the Cen­ters for Dis­ease Con­trol and Pre­ven­tion found the orga­ni­za­tion failed to meet biosafe­ty stan­dards. . . . The CDC sent a cease and desist order in July. After USAMRIID received the order from the CDC, its reg­is­tra­tion with the Fed­er­al Select Agent Pro­gram, which over­sees dis­ease-caus­ing mate­r­i­al use and pos­ses­sion, was sus­pend­ed. That sus­pen­sion effec­tive­ly halt­ed all bio­log­i­cal select agents and tox­in research at USAMRIID . . . .”

Fol­low­ing the update on the WIV and BSL‑4 lab­o­ra­to­ries, we piv­ot to analy­sis of the ele­va­tion of remde­sivir as the “go-to” treat­ment du jour for Covid-19. Of para­mount impor­tance is the remark­able time­line: The DSMB (data safe­ty and mon­i­tor­ing board) ” . . . . the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .” 

As will be seen, it was on 4/29 that Joe Gro­gan resigned. (See below.)

When pos­i­tive news on a NIAID study on the drug remde­sivir were released–on 4/29–it drove broad gains in the stock mar­ket. In FTR #1131, we not­ed that dis­clo­sures con­cern­ing pos­i­tive news about Mod­er­na’s exper­i­men­tal Covid-19 vac­cine also proved to be a sim­i­lar dri­ver of the stock mar­ket, as well as of Mod­er­na’s stock.

Dis­cus­sion of the hard details of sev­er­al remde­sivir tri­als begins with dis­cus­sion of an NIAID tri­al that helped move the mar­kets, as seen above. The tri­al was a mod­est suc­cess, indi­cat­ing that recov­ery for recent­ly infect­ed patients was about 31% faster than for place­bo. There was no sig­nif­i­cant sta­tis­ti­cal dif­fer­ence in mortality–the most impor­tant mea­sure of effec­tive­ness accord­ing to many experts.

” . . . . Dur­ing an appear­ance along­side Pres­i­dent Trump in the Oval Office, Antho­ny Fau­ci, the direc­tor of NIAID, part of the Nation­al Insti­tutes of Health, said the data are a ‘very impor­tant proof of con­cept’ and that there was rea­son for opti­mism. He cau­tioned the data were not a ‘knock­out.’ At the same time, the study achieved its pri­ma­ry goal, which was to improve the time to recov­ery, which was reduced by four days for patients on remde­sivir. The pre­lim­i­nary data showed that the time to recov­ery was 11 days on remde­sivir com­pared to 15 days for place­bo, a 31% decrease. The mor­tal­i­ty rate for the remde­sivir group was 8%, com­pared to 11.6% for the place­bo group; that mor­tal­i­ty dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant. . . .”

Next we present a Stat News arti­cle on the inter­nal delib­er­a­tions behind the deci­sions to mod­i­fy the NIAID study. Of par­tic­u­lar sig­nif­i­cance is the DSMB delib­er­a­tion. Note the time­line of the DSMB delib­er­a­tion, com­bined with the announce­ment on 4/29 that drove the mar­kets high­er.

1.–The deci­sion was made to cut it short before the ques­tion of remdesivir’s impact on mor­tal­i­ty could be answered: ” . . . .The Nation­al Insti­tute of Aller­gy and Infec­tious Dis­eases has described to STAT in new detail how it made its fate­ful deci­sion: to start giv­ing remde­sivir to patients who had been assigned to receive a place­bo in the study, essen­tial­ly lim­it­ing researchers’ abil­i­ty to col­lect more data about whether the drug saves lives — some­thing the study, called ACTT‑1, sug­gests but does not prove. In the tri­al, 8% of the par­tic­i­pants giv­en remde­sivir died, com­pared with 11.6% of the place­bo group, a dif­fer­ence that was not sta­tis­ti­cal­ly sig­nif­i­cant. A top NIAID offi­cial said he had no regrets about the deci­sion. ‘There cer­tain­ly was una­nim­i­ty with­in the insti­tute that this was the right thing to do,’ said H. Clif­ford Lane, NIAID’s clin­i­cal direc­tor. . . .”

2.–In addi­tion, patients sched­uled to receive place­bo received remde­sivir, instead. ” . . . . Steven Nis­sen, a vet­er­an tri­al­ist and car­di­ol­o­gist at the Cleve­land Clin­ic, dis­agreed that giv­ing place­bo patients remde­sivir was the right call. ‘I believe it is in society’s best inter­est to deter­mine whether remde­sivir can reduce mor­tal­i­ty, and with the release of this infor­ma­tion doing a place­bo-con­trolled tri­al to deter­mine if there is a mor­tal­i­ty ben­e­fit will be very dif­fi­cult,’ he said. ‘The ques­tion is: Was there a route, or is there a route, to deter­mine if the drug can pre­vent death?’ The deci­sion is ‘a lost oppor­tu­ni­ty,’ he said. . . .”

3.–Steven Nis­sen was not alone in his crit­i­cism of the NIAID’s deci­sion. ” . . . .Peter Bach, the direc­tor of the Cen­ter for Health Pol­i­cy and Out­comes at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter, agreed with Nis­sen. ‘The core under­stand­ing of clin­i­cal research par­tic­i­pa­tion and clin­i­cal research con­duct is we run the tri­al rig­or­ous­ly to pro­vide the most accu­rate infor­ma­tion about the right treat­ment,’ he said. And that answer, he argued, should ide­al­ly have deter­mined whether remde­sivir saves lives. The rea­son we have shut our whole soci­ety down, Bach said, is not to pre­vent Covid-19 patients from spend­ing a few more days in the hos­pi­tal. It is to pre­vent patients from dying. ‘Mor­tal­i­ty is the right end­point,’ he said. . . .”

4.–Not only was the admin­is­tra­tion of remde­sivir instead of place­bo pri­or­i­tized, but the NIAID study itself was atten­u­at­ed! ” . . . . But the change in the study’s main goal also changed the way the study would be ana­lyzed. Now, the NIAID decid­ed, the analy­sis would be cal­cu­lat­ed when 400 patients out of the 1,063 patients the study enrolled had recov­ered. If remde­sivir turned out to be much more effec­tive than expect­ed, ‘inter­im’ analy­ses would be con­duct­ed at a third and two-thirds that number.The job of review­ing these analy­ses would fall to a com­mit­tee of out­side experts on what is known as an inde­pen­dent data and safe­ty mon­i­tor­ing board, or DSMB. . . .”

5.–The per­for­mance of the DSMB for the remde­sivir study is note­wor­thy: ” . . . . But the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . .”

6.–The DSMB meet­ing on 4/27 deter­mined the switch from place­bo to remde­sivir. Of para­mount impor­tance is the fact that this was JUST BEFORE the 4/29 announce­ment that drove the mar­kets high­er and the same day on which key Trump aide–and for­mer Gilead Sci­ences lob­by­ist Joe Gro­gan resigned! ” . . . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .”

7.–Dr. Ethan Weiss gave an accu­rate eval­u­a­tion of the NIAID study: ” . . . . ‘We’ve squan­dered an incred­i­ble oppor­tu­ni­ty to do good sci­ence,’ [Dr. Ethan] Weiss said. ‘If we could ever go back and do some­thing all over, it would be the infra­struc­ture to actu­al­ly learn some­thing. Because we’re not learn­ing enough.’ . . . .”

Next, we ana­lyze a STAT News excerpt that goes into more of the con­cerns about the Gilead study design.

The Gilead study was designed with­out any con­trol group, so the ques­tion of how much remde­sivir actu­al­ly helps sick patients (or doesn’t help) can’t be defin­i­tive­ly answered by that study.

The arti­cle also gives Gilead’s expla­na­tion for why they left out a con­trol group: due to the lim­it­ed sup­plies of the drug the com­pa­ny decid­ed to pri­or­i­tize on pro­duc­ing more of the drug itself rather than a place­bo con­trol. It’s an expla­na­tion that only makes sense if pro­duc­ing place­bo dos­es was some­how a sig­nif­i­cant tech­ni­cal chal­lenge, which seems dubi­ous.

Due to a lack of a con­trol group, the study instead focus­es on answer­ing the ques­tion of whether or not the recov­ery times for patients dif­fers between groups receiv­ing a 10-day course of the drug vs a 5‑day course. The patients were severe­ly ill but not on ven­ti­la­tors when enrolled in the study (so the patients that need the drug most weren’t test­ed). The pre­lim­i­nary results released Wednes­day sug­gest there is no dif­fer­ence between the recov­ery times for the two groups.

1.–The Gilead study lacked a con­trol group: ” . . . .  But out­side experts in clin­i­cal tri­al design wor­ry that the results, instead of lead­ing to a clear pic­ture of whether the med­i­cine is effec­tive, will instead mud­dy the waters fur­ther. The main con­cern, they say, stems from the fact that the Gilead tri­al expect­ed to read out this week, which was con­duct­ed among patients with severe dis­ease, lacks a con­trol group — that is, patients who are ran­dom­ly assigned to receive the best treat­ment avail­able, but not remde­sivir. As designed, the only ran­dom­iza­tion is the dura­tion of treat­ment: either five days or 10 days of drug. With­out a true con­trol group of patients, many experts say, it will be dif­fi­cult to deter­mine whether remde­sivir is effec­tive. . . .”

2.–The above-men­tioned Steven Nis­sen summed up the use­ful­ness of the Gilead tri­al. ” . . . . ‘The over­all study itself has lit­tle or no sci­en­tif­ic val­ue since all patients are receiv­ing the drug,’ said Steven Nis­sen, the chief aca­d­e­m­ic offi­cer at the Cleve­land Clin­ic and lead inves­ti­ga­tor of many tri­als for heart drugs that have been approved by the Food and Drug Admin­is­tra­tion. ‘The study, as designed, is essen­tial­ly use­less and can­not be used by the FDA for con­sid­er­a­tion of remde­sivir for approval to treat coro­n­avirus,’ Nis­sen said. . . .”

3.–Gilead’s spokesper­son alleged that the com­pa­ny had a lim­it­ed sup­ply of place­bo and remde­sivir. ” . . . . ‘In the ear­ly stages of the pan­dem­ic, we not only had a lim­it­ed sup­ply of remde­sivir but also a lim­it­ed sup­ply of the matched place­bo required for place­bo-con­trolled stud­ies,’ said Amy Flood, a Gilead spokesper­son. ‘We chose to pri­or­i­tize man­u­fac­tur­ing active drug over place­bo, and we pro­vid­ed our sup­ply of place­bo to Chi­na and NIAID for their stud­ies of remde­sivir.’ . . .”

5.–A num­ber of crit­ics shared Steven Nis­sen’s opin­ion about the sci­en­tif­ic val­ue of the study. ” . . . . Crit­ics point to Gilead’s deci­sion to com­pare two groups giv­en remde­sivir for either five days or 10 days. The prob­lem with this strat­e­gy, they say, is that an inef­fec­tive drug that did noth­ing and a very effec­tive drug that con­sis­tent­ly helped patients over­come the virus would look the same in such a study. Only if the 10-day course were more effec­tive, or if it was worse because of side effects, would the study have any clear result. . . .”

6.–Nissen was more opti­mistic about a sec­ond forth­com­ing Gilead tri­al. Sloan Ket­ter­ing’s Peter Bach did not share that opti­mism. ” . . . .Yet anoth­er tri­al in less sick patients, also run by Gilead, does have a con­trol group and may give a clear­er answer. Nis­sen sees ‘a rea­son­able study design.’ But Bach was more crit­i­cal, say­ing that even though that study has a con­trol group, the lack of a place­bo means the study might not be trust­wor­thy. That’s because its main goal, time to improve­ment of symp­toms, could be affect­ed by the per­cep­tions of clin­i­cians and the patients them­selves. Bach said the hos­pi­tals con­duct­ing the study ‘are eas­i­ly capa­ble of wrap­ping syringes in brown paper and blind­ing the whole thing. I don’t under­stand why you would run a tri­al like this.’ . . . .”

Although it was cut short due to the wan­ing of the pan­dem­ic in Chi­na, a WHO-leaked study was not encour­ag­ing with regard to remde­sivir’s effi­ca­cy as a treat­ment for Covid-19.

1.–The Chi­nese study was a ram­dom­ized con­trolled tri­al: ” . . . . Encour­ag­ing data from patients in that study at the Uni­ver­si­ty of Chica­go were described by researchers at a vir­tu­al town hall and obtained by STAT last week. How­ev­er, unlike those data, these new results are from a ran­dom­ized con­trolled tri­al, the med­ical gold stan­dard. . . .”

2.–The Chi­nese study found that remde­sivir was of no val­ue in pre­vent­ing Covid-19 deaths. As not­ed above, the effect of the drug on mor­tal­i­ty was the main con­sid­er­a­tion. Our soci­ety has not been shut down to afford peo­ple short­er stays in the hos­pi­tal, but to pre­vent death. ” . . . . Accord­ing to the sum­ma­ry of the Chi­na study, remde­sivir was ‘not asso­ci­at­ed with a dif­fer­ence in time to clin­i­cal improve­ment’ com­pared to a stan­dard of care con­trol. After one month, it appeared 13.9% of the remde­sivir patients had died com­pared to 12.8% of patients in the con­trol arm. The dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant. . . .”

3.–The Chi­nese study pro­duced a grim assess­ment of remde­sivir: ” . . . . ‘In this study of hos­pi­tal­ized adult patients with severe COVID-19 that was ter­mi­nat­ed pre­ma­ture­ly, remde­sivir was not asso­ci­at­ed with clin­i­cal or viro­log­i­cal ben­e­fits,’ the sum­ma­ry states. The study was ter­mi­nat­ed pre­ma­ture­ly because it was dif­fi­cult to enroll patients in Chi­na, where the num­ber of Covid-19 cas­es was decreas­ing. An out­side researcher said that the results mean that any ben­e­fit from remde­sivir is like­ly to be small. ‘If there is no ben­e­fit to remde­sivir in a study this size, this sug­gests that the over­all ben­e­fit of remde­sivir in this pop­u­la­tion with advanced infec­tion is like­ly to be small in the larg­er Gilead tri­al,’ said Andrew Hill, senior vis­it­ing research fel­low at Liv­er­pool Uni­ver­si­ty. . . .”

After dis­cussing a num­ber of prob­lems that Gilead Sci­ences may encounter in the pro­duc­tion of sig­nif­i­cant quan­ti­ties of remde­sivir to be effec­tive, the broad­cast con­cludes with dis­cus­sion of the inap­pro­pri­ate­ly-named “Sci­en­tists to Stop Covid-19.”

The remark­able han­dling of the NIAID study, the tim­ing of the announce­ment of the alto­geth­er lim­it­ed suc­cess of the atten­u­at­ed tri­al, and the rise in equi­ties as a result of the announce­ment may be best under­stood in the con­text of the role played in Trump pan­dem­ic deci­sion-mak­ing by an elite group of bil­lion­aires and scientists–including Peter Thiel and con­vict­ed felon Michael Milken (the “junk bond king”).

1.–” . . . . Call­ing them­selves ‘Sci­en­tists to Stop COVID-19,’ the col­lec­tion of top researchers, bil­lion­aires and indus­try cap­tains will act as an ‘ad hoc review board’ for the tor­rent of coro­n­avirus research, ‘weed­ing out’ flawed data before it reach­es pol­i­cy­mak­ers, the Wall Street Jour­nal report­ed on Mon­day. They are also act­ing as a go-between for phar­ma­ceu­ti­cal com­pa­nies seek­ing to build a com­mu­ni­ca­tion chan­nel with Trump admin­is­tra­tion offi­cials. The group . . . . has advised Nick Ayers, an aide to Vice Pres­i­dent Mike Pence, as well as oth­er agency heads, in the past month. Pence is head­ing up the White House coro­n­avirus task force. . . .”

2.–” . . . The brainy bunch is led by Thomas Cahill, a 33-year-old doc­tor who became a ven­ture cap­i­tal­ist . . . . Cahill’s clout comes from build­ing con­nec­tions through his invest­ment firm, New­path Part­ners, with Sil­i­con Valley’s Peter Thiel, the founder of Pay­Pal, and bil­lion­aire busi­ness­men Jim Palot­ta and Michael Milken. . . .”

Note that Thiel played a dom­i­nant role in bankrolling New­path Part­ners, and the oth­er finan­cial angel who ele­vat­ed Cahill–Brian Sheth–introduced him to Tom­my Hicks, Jr., the co-chair­man of the RNC. In FTR #‘s 1111 and 1112, we looked at Hicks’ net­work­ing with Steve Ban­non asso­ciate J. Kyle Bass, as well as his role in the inter-agency net­works dri­ving the anti-Chi­na effort.

1.–” . . . . At the helm of the effort: The 33-year-old and very-much-under-the-radar ven­ture cap­i­tal­ist Tom Cahill, who leads life sci­ences-focused New­path Part­ners. Cahill com­plet­ed his M.D. and PhD at Duke Uni­ver­si­ty a mere two years ago before land­ing at blue-chip invest­ment firm Rap­tor Group through a friend. He went on to found New­path with some $125 mil­lion after impress­ing well-con­nect­ed names like ven­ture cap­i­tal­ist Peter Thiel and Vista Equi­ty Part­ners co-founder Bri­an Sheth. . . . It was through Sheth, for exam­ple, that Sci­en­tists to Stop Covid-19 con­nect­ed with the co-chair­man of the Repub­li­can Nation­al Com­mit­tee, Thomas Hicks Jr. . . .”

The fed­er­al gov­ern­men­t’s extreme focus on remde­sivir has been shaped, in large mea­sure, by the influ­ence of “Sci­en­tists to Stop COVID-19”:

1.–“Scientists to Stop Covid-19” is shep­herd­ing remde­sivir: ” . . . . Sci­en­tists to Stop COVID-19 rec­om­mends that in this phase, the U.S. Food and Drug Admin­is­tra­tion (FDA) should work to coor­di­nate with Gilead phar­ma­ceu­ti­cals to focus on expe­dit­ing the results of clin­i­cal tri­als of remde­sivir, a drug iden­ti­fied as a poten­tial treat­ment for COVID-19. The group also rec­om­mends admin­is­ter­ing dos­es of the drug to patients in an ear­ly stage of infec­tion, and notes remde­sivir will essen­tial­ly be a place­hold­er until a more effec­tive treat­ment is pro­duced.

2.–The group is doing so by atten­u­at­ing the reg­u­la­to­ry process for coro­n­avirus drugs: “Gov­ern­ment enti­ties and agen­cies appear to adhere to the rec­om­men­da­tions out­lined by the group, with the Jour­nal report­ing that the FDA and the Depart­ment of Vet­er­ans Affairs (VA) have imple­ment­ed some of the sug­ges­tions, name­ly relax­ing drug man­u­fac­tur­er reg­u­la­tions and require­ments for poten­tial coro­n­avirus treat­ment drugs. . . .”

We con­clude with a piece about the announce­ment of Grogan’s depar­ture.

” . . . . Gro­gan has served as the direc­tor of the White House Domes­tic Pol­i­cy Coun­cil since Feb­ru­ary 2019, over­see­ing a broad array of pol­i­cy issues includ­ing health care and reg­u­la­tion. . . . Gro­gan was one of the orig­i­nal mem­bers of the White House coro­n­avirus task force launched in late Jan­u­ary. . . . Gro­gan worked as a lob­by­ist for drug com­pa­ny Gilead Sci­ences before join­ing the Trump admin­is­tra­tion. . . .”

The depar­ture was announced in the Wall Street Jour­nal on the morn­ing of Wednes­day, April 29, the same day we got our first pub­lic reports of the NIAID clin­i­cal tri­al of remde­sivir that was pos­i­tive enough to show it short­ened the time to recov­ery and the same day the FDA grant­ed remde­sivir emer­gency use sta­tus. 

Note, again, the tim­ing of the DSM­B’s actions, as well as the imflu­ence of “Sci­en­tists to Stop Covid-19.”

Complications With The “Chinese-Lab-Did-It” Theory

A new arti­cle from “GMWatch” details work at the Wuhan Insti­tute of Virol­o­gy involv­ing genet­ic manip­u­la­tion of bat-borne coro­n­avirus­es sim­i­lar to the SARS CoV‑2. These manip­u­la­tions involved genet­ic engi­neer­ing tech­niques that would not be detectable as such. Most impor­tant­ly, these experiments–reported in papers pub­lished in 2017–were joint U.S.-Chinese under­tak­ings, with insti­tu­tion­al par­tic­i­pa­tion and financ­ing by orga­ni­za­tions con­nect­ed to Amer­i­can intel­li­gence and the Pen­ta­gon. Specif­i­cal­ly, the exper­i­ments were financed, in part, by USAID–a fre­quent “cut-out” for CIA and oth­er agen­cies’ “ops.” In addi­tion, the Nation­al Insti­tutes of Health were finan­cial­ly and oper­a­tional­ly involved in the experiments–NIH has net­worked with both the CIA and Pen­ta­gon on BSL‑4 (Bio-Safe­ty-Lev­el 4) projects. Worth not­ing is that the 2017 paper dis­closed that some of the work was done at a Bio-Safe­ty-Lev­el 2 lab, a rel­a­tive­ly low-secu­ri­ty insti­tu­tion. This offered a would-be male­fac­tor field intel­li­gence that would be use­ful for stag­ing a “virus-escaped-from-Chi­nese-Lab” gam­bit. A “Nature” arti­cle notes that Chi­na was about to open its first BSL‑4 lab with help from Europe. The proflif­er­a­tion of BSL‑4 labs is wor­ri­some to some observers: ” . . . . The expan­sion of BSL-4-lab net­works in the Unit­ed States and Europe over the past 15 years — with more than a dozen now in oper­a­tion or under con­struc­tion in each region — also met with resis­tance, includ­ing ques­tions about the need for so many facil­i­ties. . . . Some sci­en­tists out­side Chi­na wor­ry about pathogens escap­ing, and the addi­tion of a bio­log­i­cal dimen­sion to geopo­lit­i­cal ten­sions between Chi­na and oth­er nations.” Fur­ther­more : ” . . . . [Pro­fes­sor Richard] Ebright is not con­vinced of the need for more than one BSL‑4 lab in main­land Chi­na. He sus­pects that the expan­sion there is a reac­tion to the net­works in the Unit­ed States and Europe, which he says are also unwar­rant­ed. He adds that gov­ern­ments will assume that such excess capac­i­ty is for the poten­tial devel­op­ment of bioweapons. ‘These facil­i­ties are inher­ent­ly dual use,’ he says. . . .” In 2007, “Newsweek” fea­tured a sto­ry illus­trat­ing the use of uni­ver­si­ty BSL‑4 labs by CIA and the Pen­ta­gon, as a con­di­tion of an NIH con­tract with Boston Uni­ver­si­ty: ” . . . .The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .” The Unit­ed States Army Med­ical Research Insti­tute of Infec­tious Dis­eases has net­worked with the WIV since the mid-1980s. As we have not­ed in a num­ber of pro­grams and posts, the USAMRIID was closed down in August of 2019 for safe­ty vio­la­tions.

FTR #1130 Bio-Psy-Op Apocalypse Now, Part 6: The Magic Virus Theory, Part 3

In addi­tion to review­ing and high­light­ing cogent argu­ments that the SARS-Cov2 (Covid-19) virus may indeed have been made in a lab­o­ra­to­ry, the pro­gram exam­ines sig­nif­i­cant aspects of the hereto­fore puz­zling epi­demi­ol­o­gy of the virus. (We do NOT believe that the virus was syn­the­sized by Chi­na, as “Team Trump” is charg­ing.)

First, how­ev­er, the broad­cast sets forth infor­ma­tion about the quest for a Covid-19 vac­cine.

The make­up of Don­ald Trump’s “Oper­a­tion Warp Speed” pro­gram to devel­op a Covid-19 vac­cine in record time is alarm­ing. (No vac­cine has ever been devel­oped for human use in less than four years.)

“Oper­a­tion Warp Speed”:

1.–Is head­ed by Mon­cef Slaoui, for­mer­ly the chair­man of Mod­er­na’s prod­uct devel­op­ment com­mit­tee: ” . . . . Dr. Slaoui served on the board of Mod­er­na, a biotech­nol­o­gy com­pa­ny that has an exper­i­men­tal coro­n­avirus vac­cine that just entered Phase 2 of clin­i­cal tri­als to deter­mine if it is effec­tive. As the chair­man of the Mod­er­na board’s prod­uct devel­op­ment com­mit­tee, Dr. Slaoui might have been privy to the ear­ly indi­ca­tions of tests of whether the company’s approach appeared promis­ing, now that it is being inject­ed into human sub­jects. . . .”

2.–Is seen by Slaoui as promis­ing by Slaoui, who may well be ref­er­enc­ing tests on Mod­er­na’s mRNA vac­cine: “. . . . Dr. Slaoui, now a ven­ture cap­i­tal­ist, said that he had ‘recent­ly seen ear­ly data from a clin­i­cal tri­al with a coro­n­avirus vac­cine, and these data made me feel even more con­fi­dent that we will be able to deliv­er a few hun­dred mil­lion dos­es of vac­cine’ — enough to inoc­u­late much of the Unit­ed States — ‘by the end of 2020.’ . . . .”

3.–Will be assist­ed by a four-star gen­er­al: ” . . . . . . . . Mr. Slaoui will serve as the chief advis­er on the effort, and Gen. Gus­tave F. Per­na, a four-star gen­er­al who is in charge the Army Matériel Com­mand, will be the chief oper­at­ing offi­cer. . . .”

4.–Perna was recruit­ed by the Chair­man of the Joint Chiefs: ” . . . . Gen­er­al Per­na, who runs the Army’s com­plex sup­ply chain, said that he was asked by Gen. Mark A. Mil­ley, the chair­man of the Joint Chiefs of Staff, to help run the man­u­fac­tur­ing logis­tics relat­ed to the vac­cine devel­op­ment. . . .”

Note that Mon­cef Slaoui holds 10 mil­lion dol­lars worth of Mod­er­na stock, which has tripled in val­ue since the Covid-19 out­break began:” . . . . The for­mer phar­ma exec­u­tive tapped by Pres­i­dent Don­ald Trump to lead the fed­er­al gov­ern­men­t’s hunt for a COVID-19 vac­cine has more than $10 mil­lion in stock options in one of the com­pa­nies receiv­ing fed­er­al fund­ing. . . . Described across four sep­a­rate fil­ings, Slaoui has 155,438 options in Mod­er­na. The stake is worth $10,366,000 at Mod­er­na’s cur­rent share price, $66.69 at the time of pub­li­ca­tion. Mod­er­na shares have almost tripled in val­ue dur­ing 2020. The $66.69 fig­ure rep­re­sents an increase of  184% from the $23.46 it was trad­ing for on Jan­u­ary 1. . . .” (The day the pro­gram was record­ed, Mod­er­na’s stock increased by 25% in val­ue, and Slaoui announced he would sell his stock.)

In past posts and pro­grams, we have not­ed the Moderna–one of the com­pa­nies select­ed to devel­op a Covid-19 vac­cine, has been sub­stan­tial­ly under­writ­ten by the Pen­ta­gon (DARPA). 

Key points of dis­cus­sion in that regard:

1.–Moderna is using nov­el vac­cine tech­nol­o­gy using the injec­tion of genet­ic mate­r­i­al to cre­ate anti­bod­ies. This tech­nol­o­gy has nev­er been used on human beings. “. . . . The sec­ond phar­ma­ceu­ti­cal com­pa­ny that was select­ed by CEPI to devel­op a vac­cine for the new coro­n­avirus is Mod­er­na Inc., which will devel­op a vac­cine for the nov­el coro­n­avirus of con­cern in col­lab­o­ra­tion with the U.S. NIH and which will be fund­ed entire­ly by CEPI. The vac­cine in ques­tion, as opposed to Inovio’s DNA vac­cine, will be a mes­sen­ger RNA (mRNA) vac­cine. Though dif­fer­ent than a DNA vac­cine, mRNA vac­cines still use genet­ic mate­r­i­al ‘to direct the body’s cells to pro­duce intra­cel­lu­lar, mem­brane or secret­ed pro­teins.’ Moderna’s mRNA treat­ments, includ­ing its mRNA vac­cines, were large­ly devel­oped using a $25 mil­lion grant from DARPA and it often touts is strate­gic alliance with DARPA in press releas­es. . . .”

2.–The tech­nol­o­gy has alarm­ing pos­si­ble neg­a­tive side-effects. “. . . . Both DNA and mRNA vac­cines involve the intro­duc­tion of for­eign and engi­neered genet­ic mate­r­i­al into a person’s cells and past stud­ies have found that such vac­cines ‘pos­sess sig­nif­i­cant unpre­dictabil­i­ty and a num­ber of inher­ent harm­ful poten­tial haz­ards’ and that ‘there is inad­e­quate knowl­edge to define either the prob­a­bil­i­ty of unin­tend­ed events or the con­se­quences of genet­ic mod­i­fi­ca­tions.’ Nonethe­less, the cli­mate of fear sur­round­ing the coro­n­avirus out­break could be enough for the pub­lic and pri­vate sec­tor to devel­op and dis­trib­ute such con­tro­ver­sial treat­ments due to fear about the epi­dem­ic poten­tial of the cur­rent out­break. . . .”

3.–Looming large in the back­ground of the Mod­er­na vac­cine tech­nol­o­gy is DARPA fund­ing of “gene dri­ve” tech­nol­o­gy. “. . . . Con­cerns about Pen­ta­gon exper­i­ments with bio­log­i­cal weapons have gar­nered renewed media atten­tion, par­tic­u­lar­ly after it was revealed in 2017 that DARPA was the top fun­der of the con­tro­ver­sial ‘gene dri­ve’ tech­nol­o­gy, which has the pow­er to per­ma­nent­ly alter the genet­ics of entire pop­u­la­tions while tar­get­ing oth­ers for extinc­tion. At least two of DARPA’s stud­ies using this con­tro­ver­sial tech­nol­o­gy were clas­si­fied and ‘focused on the poten­tial mil­i­tary appli­ca­tion of gene dri­ve tech­nol­o­gy and use of gene dri­ves in agri­cul­ture,’ accord­ing to media reports. . . . Co-direc­tor of the ETC Group Jim Thomas said that this tech­nol­o­gy may be used as a bio­log­i­cal weapon: ‘Gene dri­ves are a pow­er­ful and dan­ger­ous new tech­nol­o­gy and poten­tial bio­log­i­cal weapons could have dis­as­trous impacts on peace, food secu­ri­ty and the envi­ron­ment, espe­cial­ly if mis­used, The fact that gene dri­ve devel­op­ment is now being pri­mar­i­ly fund­ed and struc­tured by the US mil­i­tary rais­es alarm­ing ques­tions about this entire field.’ . . . . How­ev­er, the ther­a­pies being devel­oped by Inovio, Mod­er­na and the Uni­ver­si­ty of Queens­land are in align­ment with DARPA’s objec­tives regard­ing gene edit­ing and vac­cine tech­nol­o­gy. For instance, in 2015, DARPA geneti­cist Col. Daniel Wat­ten­dorf described how the agency was inves­ti­gat­ing a ‘new method of vac­cine pro­duc­tion [that] would involve giv­ing the body instruc­tions for mak­ing cer­tain anti­bod­ies. Because the body would be its own biore­ac­tor, the vac­cine could be pro­duced much faster than tra­di­tion­al meth­ods and the result would be a high­er lev­el of pro­tec­tion.’ . . . .”

As dis­cussed in FTR #1124–among oth­er programs–it is now pos­si­ble to cre­ate ANY virus from scratch, using “mail-order” or “design­er” genes. In FTR #282–recorded in May of 2001–we not­ed the ter­ri­ble sig­nif­i­cance of the devel­op­ment of such “Design­er Gene” tech­nol­o­gy.

A BBC sto­ry from 1999 high­lights the fears of experts that the advent of such tech­nol­o­gy could enable the devel­op­ment of eth­no-spe­cif­ic bio­log­i­cal weapons: ” . . . . Advances in genet­ic knowl­edge could be mis­used to devel­op pow­er­ful bio­log­i­cal weapons that could be tai­lored to strike at spe­cif­ic eth­nic groups, the British Med­ical Asso­ci­a­tion has warned. A BMA report Biotech­nol­o­gy, Weapons and Human­i­ty says that con­cert­ed inter­na­tion­al action is nec­es­sary to block the devel­op­ment of new, bio­log­i­cal weapons.  . . . The BMA report warns that legit­i­mate research into micro­bi­o­log­i­cal agents and genet­i­cal­ly tar­get­ed ther­a­peu­tic agents could be dif­fi­cult to dis­tin­guish from research geared towards devel­op­ing more effec­tive weapons. . . . Dr Vivi­enne Nathanson, BMA Head of Health Pol­i­cy Research said:  ‘The his­to­ry of human­i­ty is a his­to­ry of war. Sci­en­tif­ic advances quick­ly lead to devel­op­ments in weapons tech­nol­o­gy. . . .‘Biotech­nol­o­gy and genet­ic knowl­edge are equal­ly open to this type of malign use. . . .”

We high­light infor­ma­tion pre­sent­ed in FTR #1129, for pur­pos­es of empha­siz­ing the flim­sy nature of the argu­ment pre­sent­ed in a paper from Nature Med­i­cine.

Many sci­en­tif­ic and med­ical peo­ple dis­miss­ing the argu­ment that the Covid-19 coro­n­avirus may have been cre­at­ed in a lab­o­ra­to­ry may be act­ing out of the sin­cere desire to pre­clude a full-dress Cold War between the U.S. and Chi­na. The Trump admin­is­tra­tion has tire­less­ly flogged the “Chi­na did it and it came from a lab­o­ra­to­ry” meme. Many lib­er­als who dis­missed the obvi­ous fact that Pres­i­dent Kennedy was mur­dered by a cabal of pow­er­ful U.S. nation­al secu­ri­ty inter­ests did so because of what Peter Dale Scott calls a “lev­el one cover-up”–alleged Sovi­et and/or Cas­tro Cuban manip­u­la­tion of Lee Har­vey Oswald, fab­ri­cat­ed by the exe­cu­tion­ers them­selves.

Two telling, thought­ful, sub­stan­tive cri­tiques of the Nature Med­i­cine arti­cle shed light on the flim­sy nature of its argu­ments.

It would not be unfair to char­ac­ter­ize the arti­cle as “The War­ren Report” of the Covid-19 pan­dem­ic.

Genet­ic Engi­neer­ing

Like the Bible, it is open to seri­ous sci­en­tif­ic refu­ta­tion: ” . . . . To put it sim­ply, the authors are say­ing that SARS-CoV­‑2 was not delib­er­ate­ly engi­neered because if it were, it would have been designed dif­fer­ent­ly. How­ev­er, the Lon­don-based mol­e­c­u­lar geneti­cist Dr Michael Anto­niou com­ment­ed that this line of rea­son­ing fails to take into account that there are a num­ber of lab­o­ra­to­ry-based sys­tems that can select for high affin­i­ty RBD vari­ants that are able to take into account the com­plex envi­ron­ment of a liv­ing organ­ism. This com­plex envi­ron­ment may impact the effi­cien­cy with which the SARS-CoV spike pro­tein can find the ACE2 recep­tor and bind to it. An RBD select­ed via these more real­is­tic real-world exper­i­men­tal sys­tems would be just as ‘ide­al’, or even more so, for human ACE2 bind­ing than any RBD that a com­put­er mod­el could pre­dict. And cru­cial­ly, it would like­ly be dif­fer­ent in amino acid sequence. So the fact that SARS-CoV­‑2 doesn’t have the same RBD amino acid sequence as the one that the com­put­er pro­gram pre­dict­ed in no way rules out the pos­si­bil­i­ty that it was genet­i­cal­ly engi­neered. . . .”

Dr. Michael Anto­niou notes that dif­fer­ent genet­ic engi­neer­ing process­es than the one high­light­ed in the Nature Med­i­cine paper can be used: ”  . . . . There is anoth­er method by which an enhanced-infec­tiv­i­ty virus can be engi­neered in the lab. A well-known alter­na­tive process that could have been used has the cum­ber­some name of “direct­ed iter­a­tive evo­lu­tion­ary selec­tion process”. In this case, it would involve using genet­ic engi­neer­ing to gen­er­ate a large num­ber of ran­dom­ly mutat­ed ver­sions of the SARS-CoV spike pro­tein recep­tor bind­ing domain (RBD), which would then be select­ed for strong bind­ing to the ACE2 recep­tor and con­se­quent­ly high infec­tiv­i­ty of human cells. . . .”

The notion that the “Nature Med­i­cine” authors had not heard of the above process is not cred­i­ble: ” . . . . Such a direct­ed iter­a­tive evo­lu­tion­ary selec­tion process is a fre­quent­ly used method in lab­o­ra­to­ry research. So there is lit­tle or no pos­si­bil­i­ty that the Nature Med­i­cine arti­cle authors haven’t heard of it – not least, as it is con­sid­ered so sci­en­tif­i­cal­ly impor­tant that its inven­tors were award­ed the Nobel Prize in Chem­istry in 2018. . . .”

Of more than pass­ing sig­nif­i­cance is anoth­er arti­cle that finds seri­ous fault with the “Nature Med­i­cine” paper. ” . . . . Pro­fes­sor Stu­art New­man, pro­fes­sor of cell biol­o­gy and anato­my at New York Med­ical Col­lege, says that a key argu­ment used to deny that it could be a genet­i­cal­ly engi­neered strain that escaped from a lab­o­ra­to­ry actu­al­ly points to the exact oppo­site. In oth­er words, it indi­cates that SARS-CoV­‑2 could well be genet­i­cal­ly engi­neered and that it could have escaped from a lab. . . . As Adam Lau­r­ing, an asso­ciate pro­fes­sor of micro­bi­ol­o­gy, immunol­o­gy and infec­tious dis­eases at the Uni­ver­si­ty of Michi­gan Med­ical School, has not­ed, Andersen’s paper argues that, ‘the SARS-CoV­‑2 virus has some key dif­fer­ences in spe­cif­ic genes rel­a­tive to pre­vi­ous­ly iden­ti­fied coro­n­avirus­es – the ones a lab­o­ra­to­ry would be work­ing with. This con­stel­la­tion of changes makes it unlike­ly that it is the result of a lab­o­ra­to­ry ‘escape’.‘But Pro­fes­sor New­man says that this is total­ly uncon­vinc­ing because ‘The ‘key dif­fer­ences’ were in regions of the coro­n­avirus spike pro­tein that were the sub­ject of genet­ic engi­neer­ing exper­i­ments in labs around the world (main­ly in the US and Chi­na) for two decades.’ . . .”

Pro­fes­sor New­man goes on to high­light oth­er, seri­ous flaws in the argu­ment: ” . . . In an email inter­view with GMWatch, New­man, who is edi­tor-in-chief of the jour­nal Bio­log­i­cal The­o­ry and co-author (with Tina Stevens) of the book Biotech Jug­ger­naut, ampli­fied this spec­u­la­tion by not­ing, ‘The Nature Med­i­cine paper points to vari­a­tions in two sites of the spike pro­tein of the new coro­n­avirus that the authors claim must have arisen by nat­ur­al selec­tion in the wild. How­ev­er, genet­ic engi­neer­ing of one of these sites, the ACE2 recep­tor bind­ing domain, has been pro­posed since 2005 in order to help gen­er­ate vac­cines against these virus­es (see this paper). It is puz­zling that the authors of the Nature Med­i­cine com­men­tary did not cite this paper, which appeared in the promi­nent jour­nal Sci­ence.’ More­over, New­man added, “The sec­ond site that Ander­sen et al. assert arose by nat­ur­al means, a tar­get of enzyme cleav­age not usu­al­ly found in this class of virus­es, was in fact intro­duced by genet­ic engi­neer­ing in a sim­i­lar coro­n­avirus in a paper they do cite. This was done to explore mech­a­nisms of path­o­genic­i­ty. . . . .”

Worth not­ing, again, is the British Med­ical Asso­ci­a­tion’s warn­ing dis­cussed in FTR #1129, as well as above: ” . . . .The BMA report warns that legit­i­mate research into micro­bi­o­log­i­cal agents and genet­i­cal­ly tar­get­ed ther­a­peu­tic agents could be dif­fi­cult to dis­tin­guish from research geared towards devel­op­ing more effec­tive weapons. . . .”

As the GMWatch authors con­clude: ” . . . . Such ‘enhanced infec­tiv­i­ty’ research is car­ried out on virus­es all over the world (and not just in Chi­na) to inves­ti­gate their behav­iour and to devel­op vac­cines and oth­er ther­a­pies, as well as for ‘biode­fence’ pur­pos­es. . . .”

Reports are now emerg­ing of pos­si­ble Covid-19 infec­tion among ath­letes who par­tic­i­pat­ed at the Mil­i­tary World Games in Wuhan in Octo­ber 19. 

We have spec­u­lat­ed at some length about the pos­si­bil­i­ty that infect­ing those very healthy, superbly-con­di­tioned indi­vid­u­als might have been an excel­lent vehi­cle for spread­ing the virus around the world. 

Fur­ther dis­cus­sion of this can be found in FTR #‘s 1118 and 1122. We note that Chi­na has spec­u­lat­ed about the Wuhan Mil­i­tary World Games being a vehi­cle for the U.S. to spread the infec­tion.

We have not­ed that lan­guage is, past a point, inad­e­quate to ana­lyze and dis­cuss some of the major con­sid­er­a­tions in the Covid-19 “op.” A bio-weapons would require a very small num­ber of agents in order to be effec­tive­ly dis­sem­i­nat­ed. In addi­tion, we note that–in the age of mind control–an oper­a­tive can be dis­pensed to per­form a func­tion with­out their knowl­edge.

In addi­tion to French ath­letes, con­tin­gents from Swe­den, Spain and Italy appear to have become infect­ed. The appar­ent infec­tion of the French ath­letes pre-dates the first con­firmed case in Chi­na by 20 days.

A fish mer­chant who worked near Charles De Gaulle Air­port test­ed pos­i­tive for the virus on Decem­ber 27.

The appar­ent­ly infect­ed ath­letes par­tic­i­pat­ing in the Mil­i­tary World Games fur­ther com­pli­cates the puz­zling epi­demi­ol­o­gy of the virus.

Doc­tors quot­ed in a New York Times piece under­score the anom­alous epi­demi­ol­o­gy of the virus: ” . . . . In San Jose, tis­sue sam­pling from a woman who died on Feb. 6 revealed that she was prob­a­bly the first known per­son in the U.S. whose death was linked to the coro­n­avirus — a strong sign that the virus may have been cir­cu­lat­ing in that part of North­ern Cal­i­for­nia in Jan­u­ary. But was it part of a large, pre­vi­ous­ly unrec­og­nized out­break? . . .

“. . . . Dr. George Ruther­ford, a pro­fes­sor of epi­demi­ol­o­gy and bio­sta­tis­tics at the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co, the­o­rized that per­haps the woman, who worked for a com­pa­ny that had an office in Wuhan, was one of only a small num­ber of peo­ple who con­tract­ed the virus at that time and that trans­mis­sions prob­a­bly petered out for some rea­son. Oth­er­wise, he said, the region would have seen a much big­ger out­break. . . .

“. . . . Dr. [Trevor] Bed­ford said he also believed this was the more like­ly sce­nario, not­ing that up to half of peo­ple with coro­n­avirus infec­tions have no symp­toms. . . .

“. . . . There could have been a tiny num­ber of iso­lat­ed coro­n­avirus cas­es among trav­el­ers to the Unit­ed States in Decem­ber, Dr. Bed­ford said. But it is pret­ty clear that none of them spread.

“In part, sci­en­tists can tell that by look­ing at the genom­ic fin­ger­prints of each case. But anoth­er clue is the rapid rate at which the virus spreads, Dr. Ruther­ford said. . . . Researchers are not see­ing any chains that appear to go that far back. . . .”

Lead­ing the Trump admin­is­tra­tion’s rhetor­i­cal and polit­i­cal charge against Chi­na is Mike Pom­peo. Charg­ing that the virus “escaped” from a lab in Wuhan and equiv­o­cat­ing about whether that release was inten­tion­al, Koch broth­ers-pro­tege Pom­peo cit­ed alleged duplic­i­ty on behalf of Chi­na’s com­mu­nist par­ty in con­nec­tion with the virus. ” . . . . ‘I can tell you that there is a sig­nif­i­cant amount of evi­dence that this came from that lab­o­ra­to­ry in Wuhan,’ Pom­peo said on ABC’s ‘This Week’ Sun­day. ‘Do you think they inten­tion­al­ly released that virus, or it was an acci­dent in the lab?’ Co-Anchor Martha Rad­datz pressed. ‘I can’t answer your ques­tion about that,’ he said, ‘because the Chi­nese Com­mu­nist Par­ty has refused to coop­er­ate with world health experts.’ . . .”

The Chi­nese med­ical and sci­en­tif­ic estab­lish­ment has worked close­ly with coun­ter­parts glob­al­ly in an attempt to ana­lyze and treat the virus.

The high­ly anom­alous epi­demi­ol­o­gy, the lack of symp­toms in half of infect­ed patients, the wide vari­ety of symp­toms the virus caus­es and, last­ly, the fact that this was a nov­el virus and result­ing infec­tion are all fac­tors to be con­sid­ered in eval­u­at­ing the time­li­ness of the Chi­nese response.

Pom­peo also asserts that the virus was not made in a lab­o­ra­to­ry.

Next, we high­light a mis­lead­ing sto­ry in Rupert Mur­doch’s “The Dai­ly Tele­graph” out of Syd­ney, Aus­tralia. The sto­ry alleges that the Five Eyes elec­tron­ic intel­li­gence net­work has cor­rob­o­rat­ed the “it came from a Chi­nese lab” meme.

Of more than pass­ing inter­est is the dis­clo­sure that the project on bat-borne coro­n­avirus­es con­duct­ed in the Wuhan lab­o­ra­to­ry was a joint U.S./Chinese project, and that Ralph Bar­ic was a key Amer­i­can part­ner in the project.

This is the under­tak­ing about which we have report­ed and dis­cussed exten­sive­ly in the past! ” . . . . One of Dr Shi’s co-authors on that paper, Pro­fes­sor Ralph Bar­ic from North Car­oli­na Uni­ver­si­ty, said in an inter­view with ‘Sci­ence Dai­ly’ at the time: ‘This virus is high­ly path­o­gen­ic and treat­ments devel­oped against the orig­i­nal SARS virus in 2002 and the ZMapp drugs used to fight ebo­la fail to neu­tralise and con­trol this par­tic­u­lar virus.’ . . . .”

Bar­ic was the selectee to recon­struct the SARS Cov2 virus from scratch. Note that the arti­cle below dis­cuss­es the U.S. sus­pen­sion of the “gain of func­tion” exper­i­ments and 2017 resump­tion of same, some­how spin­ning this into the “Chi­na did it” dis­in­for­ma­tion.

The mil­i­tary has links to the Wuhan lab in ques­tion: ” . . . . Fur­ther­more, DARPA and the Pentagon’s past his­to­ry with bioweapons and their more recent exper­i­ments on genet­ic alter­ation and extinc­tion tech­nolo­gies as well as bats and coro­n­avirus­es in prox­im­i­ty to Chi­na have been large­ly left out of the nar­ra­tive, despite the infor­ma­tion being pub­licly avail­able. Also left out of the media nar­ra­tive have been the direct ties of both the USAMRIID and DARPA-part­nered Duke Uni­ver­si­ty to the city of Wuhan, includ­ing its Insti­tute of Med­ical Virol­o­gy. . . .”

A “Guardian” arti­cle sources UK intel­li­gence assets claim­ing that the 15-page dossier didn’t come from a Five Eyes intel­li­gence assess­ment. They assert that it was based on open-source mate­ri­als and put for­ward by the US as “a tool for build­ing a counter-nar­ra­tive and apply­ing pres­sure to Chi­na.”

We con­clude with analy­sis of Trump’s deputy nation­al secu­ri­ty advis­er.

Against the back­ground of the Trump admin­is­tra­tion’s anti-Chi­na cam­paign rhetoric and attempts to pin the blame for Covid-19 on a “lab­o­ra­to­ry” leak and/or delib­er­ate release, we note that the offen­sive is being pushed by The Don­ald’s deputy nation­al secu­ri­ty advis­er Matthew Pot­tinger.

“. . . . Matthew Pot­tinger, the deputy nation­al secu­ri­ty advis­er who report­ed on SARS out­breaks as a jour­nal­ist in Chi­na, pressed intel­li­gence agen­cies in Jan­u­ary to gath­er infor­ma­tion that might sup­port any ori­gin the­o­ry linked to a lab. . . .”

Pot­tinger is the son of for­mer Assis­tant Attor­ney Gen­er­al J. Stan­ley Pot­tinger.

Pot­tinger, Senior was: Assis­tant Attor­ney Gen­er­al for Civ­il Rights under Nixon and Ford; report­ed by Don­ald Freed and Fred Lan­dis (in “Death in Wash­ing­ton”) to have foiled inves­ti­ga­tions into the assas­si­na­tions of Mar­tin Luther King and Orlan­do Lete­lier; the attor­ney for the Hashe­mi broth­ers in the Octo­ber Sur­prise inves­ti­ga­tion; a close per­son­al friend of George H.W. Bush (for whom CIA head­quar­ters was named) and, last but cer­tain­ly not least, Glo­ria Steinem’s lover for nine years.

Despite the fact that Steinem tout­ed her CIA back­ground as good jour­nal­is­tic cre­den­tials in both “The New York Times” and “The Wash­ing­ton Post” (both with long-stand­ing CIA links them­selves), Pot­tinger has defend­ed her against charges that she worked for the CIA!!

Worth not­ing, as well, is the fact that the Lete­lier assas­si­na­tion was one of the mur­ders con­duct­ed under Oper­a­tion Con­dor, assist­ed by the CIA. Lete­lier was killed by a car bomb in Wash­ing­ton D.C., while J.Stanley Pot­tinger’s good friend George H.W. Bush was in charge of the CIA when Lete­lier was hit.

(We have cov­ered Oper­a­tion Con­dor in numer­ous pro­grams, includ­ing AFA #19. One of the oper­a­tional cen­ters of Con­dor was the Chilean Nazi enclave Colo­nia Dig­nidad. In FTR #839, we set forth author Peter Lev­en­da’s brave, fright­en­ing vis­it to “The Colony.” This should be digest­ed by any­one inter­est­ed in the his­to­ry of which Pot­tinger, Sr., is a part.)

One won­ders if Matthew may have fol­lowed J. Stan­ley into the CIA, if in fact Dad­dio is Agency, as Mr. Emory sus­pects.

In FTR #s 998, 999, 1000, we set forth what Mr. Emory calls “weaponized fem­i­nism.” Refash­ion­ing the doc­trine of advanc­ing the cause of women into a legal and polit­i­cal weapon for destroy­ing tar­get­ed men, dom­i­nant man­i­fes­ta­tions of the #MeToo move­ment have served the cause of the far right.

Resembling–in its essence–the “libid­i­nal McCarthy­ism” of Arthur Miller’s play “The Cru­cible,”  many high-pro­file man­i­fes­ta­tions of #MeToo have been pro­pelled by evi­den­tiary mate­r­i­al that ranges from dubi­ous to ludi­crous to non-exis­tent.

We find it more than coin­ci­den­tal that Bernie Sanders sup­port­er Tara Read­e’s shape-shift­ing accu­sa­tions against Joe Biden have sur­faced decades after the alleged incident–coinciding with Biden’s chal­leng­ing of Trump and with Pot­tinger, Jr. help­ing to direct the admin­is­tra­tion’s traf­fic.

Moderna, The Military, Medicine and Money

In past posts and pro­grams, we have not­ed that Moderna–which has been select­ed to devel­op a Covid-19 vaccine–has been sub­stan­tial­ly under­writ­ten by the Pen­ta­gon (DARPA). The vac­cine they are devel­op­ing is a mRNA (mes­sen­ger RNA) vaccine–a type of vac­cine that has nev­er been admin­is­tered to human sub­jects and is seen as very risky: ” . . . . Both DNA and mRNA vac­cines involve the intro­duc­tion of for­eign and engi­neered genet­ic mate­r­i­al into a person’s cells and past stud­ies have found that such vac­cines ‘pos­sess sig­nif­i­cant unpre­dictabil­i­ty and a num­ber of inher­ent harm­ful poten­tial haz­ards’ and that ‘there is inad­e­quate knowl­edge to define either the prob­a­bil­i­ty of unin­tend­ed events or the con­se­quences of genet­ic mod­i­fi­ca­tions.’ . . .” The head of Trump’s “Oper­a­tion Warp Speed” coro­n­avirus vac­cine pro­gram is Mon­cef Slaoui, for­mer­ly in charge of Mod­er­na’s prod­uct devel­op­ment com­mit­tee. He says that he had ” . . . .‘recent­ly seen ear­ly data from a clin­i­cal tri­al with a coro­n­avirus vac­cine, and these data made me feel even more con­fi­dent that we will be able to deliv­er a few hun­dred mil­lion dos­es of vac­cine’ — enough to inoc­u­late much of the Unit­ed States — ‘by the end of 2020. . . .” This despite the fact that no vac­cine has been approved for human use in less than four years. Slaoui will be assist­ed by Gen­er­al Gus­tave F. Per­na, whose appoint­ment was facil­i­tat­ed by Gen­er­al Mark A. Mil­ley, Chair­man of the Joint Chiefs. Inter­est­ing­ly, Slaoui holds more than $10 mil­lion worth of Mod­er­na stock, which has increased 184% since the begin­ning of the year, due to ” . . . . more than $400 mil­lion from the fed­er­al gov­ern­ment to assist tri­als of a coro­n­avirus vac­cine. . . .”

Custom Search

Recommended Reading

Dreamer of the Day Francis Parker Yockey and the Postwar Fascist International; by Kevin... Read more »